Printer Friendly

TRINITY BIOTECH PLC ANNOUNCES THE OFFICIAL OPENING OF ITS NEW MANUFACTURING FACILITY IN DUBLIN

 DUBLIN, Ireland, Sept. 16 /PRNewswire/ -- Trinity Biotech plc (NASDAQ: HIVSY, HIVWS, HIVZF) announced today that the Irish government minister of commerce, Seamus Brennan, performed the official opening of its new 10,000-square-foot manufacturing plant in Dublin last Friday, Sept. 10. The new fully equipped facility is an integrated manufacturing, research and development, and administrative unit which is currently capable of producing 6 million HIV saliva kits per year.
 The opening occurred ahead of schedule and, as stated by the minister, "is an excellent example of how technology can improve diagnosis -- in this case saliva sampling rather than conventional methods such as blood tests..." He then added, "Trinity Biotech is the fifth Irish company to trade in the U.S. stock market and I look forward to many more technology-led companies following their lead."
 Responding to the minister, Dr. Anthony C. Nicholls, CEO of Trinity Biotech remarked that the Irish government, through its Industrial Development Agency, had invested a total of $840,000 in the company by way of a stock placement. "We are pleased to have such a positive independent endorsement of our company and its plans. The company has completed the development of, and put into commercial production, its rapid HIV 1/2 saliva and HIV 1/2 blood tests. Both of these products are in clinical trials for regulatory approval in various countries worldwide. The company's HIV 1/2 rapid saliva test is the only such test in existence or available for sale worldwide, having recently been approved for sale in Ireland," said Dr. Nicholls. "With the ability to double the current capacity at a very modest cost, it is anticipated this facility will be utilized for many years. The current favorable tax treatments available in Ireland greatly enhance the plant's profit potential," he added.
 Appointment of New Investor Relations Firm
 Trinity Biotech has retained the services of Innovative Research Associates, Inc., a corporate/financial relations firm based in New York City. Innovative Research Associates, Inc. has extensive expertise in the marketing of small to mid-size cap companies in the biotechnology, electronics, industrial and other high-technology businesses to Wall Street. The firm will be very proactive in the presentation of Trinity Biotech to analysts, brokers, portfolio and investment advisors in the United States.
 -0- 9/16/93
 /CONTACT: Ronan O'Caoimh of Trinity Biotech, 01-29-55-1111, or Michael Hubard of Sovereign Ventures, 503-227-0643, or Thomas M. Dean of Innovative Research Associates, 212-421-2543/
 (HIVSY)


CO: Trinity Biotech plc; Innovative Research Associates, Inc. ST: New York IN: MTC SU:

SM-CK -- NY042 -- 2655 09/16/93 11:42 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 16, 1993
Words:426
Previous Article:ROLLS-ROYCE LAUNCHES 1994 MODELS: UNVEILS NEW BUSINESS STRATEGY
Next Article:LASERTECHNICS ANNOUNCES FORMATION OF NEW IMAGING COMPANY
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters